Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 14/20 | 0.47 |
| ▸ | MCHR2 | Q969V1 | 7/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 2/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521061 | 0.89 | HDAC3 (0.47) | MCHR1MCHR2HTR2AHTR2CHTR2B | |
| SCHEMBL538977 | 0.88 | MCHR1 (0.53) | MCHR1MCHR2 | |
| SCHEMBL6069601 | 0.87 | MCHR1 (0.52) | MCHR1MCHR2BCHECNR2SIGMAR1 | |
| SCHEMBL4539220 | 0.82 | MCHR1 (0.47) | MCHR1MCHR2HTR2AHTR2CHTR2B | |
| SCHEMBL17678169 | 0.82 | KMO (0.58) | MCHR1MCHR2SIGMAR1 | |
| SCHEMBL17678223 | 0.82 | KMO (0.58) | MCHR1MCHR2BCHECNR2CNR1 | |
| SCHEMBL22890607 | 0.79 | MCHR1 (0.45) | MCHR1MCHR2SIGMAR1 | |
| SCHEMBL21026147 | 0.79 | MCHR1 (0.47) | MCHR1MCHR2SIGMAR1 | |
| SCHEMBL21026066 | 0.79 | HTR7 (0.51) | MCHR1MCHR2 | |
| SCHEMBL29644009 | 0.79 | MCHR1 (0.45) | MCHR1MCHR2SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885HTR2A 71/4885 |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | MCHR1 1/4885MCHR2 2/4885HTR2A 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.